ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes. It operates in two segments, Nuclear Fuels and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which selectively ionizes and separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry; Silicon-28, which is used in semiconductors; and Carbon-14 for pharmaceuticals and agrochemicals. In addition, the company develops Zinc-67/68, Nickel-68, and Xenon 129/136 for the nuclear medical industry; Lithium-6, Lithium-7, Uranium-235, Chlorine-37, and Thorium Fluoride for the energy industry; and Germanium-70/72/74. ASP Isotopes Inc. was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

Period	TotalRevenue
2022-12-31	N/A
2023-12-31	$433.03K
2024-12-31	$4.14M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASPI	$4.46	+9.46%	3.51M
3
4
5

ASP Isotopes Inc. (ASPI) Revenue History

Revenue Data

Get ASP Isotopes Inc. Data in Excel

More ASPI Financial Data